Definition
The process of testing potential new therapies in animal and cell-based test systems prior to their study in patients in order to assure their potential safety and efficacy.
Characteristics
It was recognized many years ago that potential medicines were often “poisons” so that some form of screening in animal models was required before new drugs could be tried in patients. For all types of medicines, it has been generally agreed that these tests should take the form of both pharmacological and toxicological studies in animals to avoid patients being exposed to drugs that are excessively toxic or without evidence of potential efficacy. Added impetus has come from the Nuremberg Code that was formulated after the trials of the Nazi doctors convicted for the conduct of horrific medical experiments on prisoners. While this code deals primarily with the consent of volunteers and patients, one...
References
Greaves P, Williams A, Eve M (1997) First dose of potential medicines to humans: how animals help. Nat Rev Drug Discov 3:226–236
Schuster E (1997) Fifty years later: the significance of the Nuremberg Code. N Engl J Med 337:1436–1440
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag Berlin Heidelberg
About this entry
Cite this entry
Greaves, P. (2015). Preclinical Testing. In: Schwab, M. (eds) Encyclopedia of Cancer. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-27841-9_4718-2
Download citation
DOI: https://doi.org/10.1007/978-3-642-27841-9_4718-2
Received:
Accepted:
Published:
Publisher Name: Springer, Berlin, Heidelberg
Online ISBN: 978-3-642-27841-9
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences